A Phase 1/2 interventional study of Carfilzomib and Dexamethasone in Ovarian Cancer, Renal Cancer and Non-small Cell Lung Cancer, sponsored by Amgen. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by Amgen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Ovarian Neoplasms by Amgen — none open to participants now, 1 under way, 1 of them phase 3. Ovarian Neoplasms · Amgen.
Among the 17 studies in Ovarian Neoplasms by Amgen, this one is the 6th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2007, is the only one in phase 1/2, and was the 7th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 17 studies in Ovarian Neoplasms by Amgen is open now. The open studies under Ovarian Neoplasms, anywhere →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 4 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 184 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 153 across the 14 interventional studies, 1,316 across the 2 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Ovarian Neoplasms by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this Phase 1b/2 study were as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease related
Phase 1 Subjects (Bolus and Infusion):
Solid Tumor:
Multiple Myeloma (MM):
Lymphoma:
Phase 2 Bolus Subjects:
-Histologically confirmed advanced solid tumor diagnosis and:
Demographic
Laboratory
(ANC) > 1000/mm³, ≥ 8 gm/dL for solid tumors or 7.0 gm/dL for MM, and count ≥ 100,000/mm³ for solid tumors or ≥ 30,000/mm³ for MM.
Ethical/Other
Exclusion Criteria:
Disease Related
Concurrent Conditions
Subjects at risk* in whom the required program of oral and intravenous fluid hydration is , e.g., due to pre-existing pulmonary, cardiac, or renal impairment
Ethical / Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib · Drug: Dexamethasone
Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
Drug: Carfilzomib · Drug: Dexamethasone
Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
Also known as: Kyprolis
Administered orally or by IV infusion prior to carfilzomib
Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT)
Participants were evaluated for dose-limiting toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0. A DLT was defined as treatment-related ≥ Grade 2 neuropathy with pain, ≥ Grade 3 non-hematologic toxicity, Grade 4 neutropenia or thrombocytopenia lasting 7 or more days, or thrombocytopenia with bleeding. The maximum tolerated dose (MTD) for each of the 3 populations (solid tumor, multiple myeloma, and lymphoma) was defined as the dose level at which \< 33% of participants experienced a dose-limiting toxicity during the first 28-day cycle.
Time frame: 28 days
Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles
Overall response is defined as participants with a best overall response of complete response (CR), partial response (PR) or stable disease (SD) after 4 cycles, assessed by the Investigator using tumor measurement and according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target and non-target lesions and no new lesions; PR: Disappearance of all target lesions, persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits and no lesions, or, at least a 30% decrease in the size of target lesions and no progression of existing non-target lesions or any new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest size since the treatment started, and no progression of existing non-target lesions or any new lesions.
Time frame: 4 months
Percentage of Participants With an Overall Response Throughout the Study
Solid tumor participants were evaluated for disease response according to RECIST, Version 1.1. Multiple myeloma participants were evaluated using the International Myeloma Working Group (IMWG) Uniform Response Criteria with the addition of minimal response (MR) based on the European Group for Blood and Marrow Transplant Group (EBMT). Non-Hodgkin lymphoma (NHL) participants were evaluated using the International Workshop NHL criteria. Waldenström macroglobulinemia (WM) participants were evaluated using Criteria from the Sixth International Workshop for WM. Overall response is defined in Outcome Measure 2 for participants with solid tumors. For NHL, overall response is defined as a best overall response of CR or PR. For multiple myeloma and WM, overall response is defined as participants with a best overall response of stringent complete response (sCR), CR, very good partial response (VGPR) or PR.
Time frame: Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.
Duration of Response
Duration of response is defined as the time from first evidence of a partial response or better (the first observation of PR before confirmation) to disease progression, with deaths owing to causes other than progression censored.
Time frame: Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.
Progression-Free Survival
Progression-free survival (PFS) is the time from start of treatment to disease progression or death (due to any cause), whichever occurred first.
Time frame: Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.
Time to Progression
Time to Progression (TTP) is defined as number of months between start of treatment and first evidence/documentation of disease progression.
Time frame: Tumor assessments occurred at the end of Cycle 2, 4, 6, 9, and 12 and continued every 3 cycles thereafter up to 6 months after last dose. Analysis includes data up to the data cut-off date of 07 October 2014; maximum duration of treatment was 35 months.
Maximum Observed Plasma Concentration of Carfilzomib
Plasma concentrations of carfilzomib were determined by a validated liquid chromatography tandem mass spectrometry method. Concentration values that were below the lower limit of quantification of 0.1 ng/mL were set to zero. Treatment groups receiving the same dose (e.g. 20 mg/m²) were combined for Day 1 analyses.
Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib
Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib
Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib
Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Elimination Half-life (t½) of Carfilzomib
Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Clearance (CL) of Carfilzomib
Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Volume of Distribution at Steady State (Vss) of Carfilzomib
Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib
Time frame: Cycle 1, Day 1, predose and at 5 minutes and 15 minutes post start of infusion (for 30-minute infusion groups only), and at the end of infusion, 5, 15, and 30 minutes; and 1, 2, and 4 hours after the end of the infusion.
Patients with relapsed solid tumors (non-small and small cell lung, ovarian, renal, any other solid tumor type), multiple myeloma or lymphoma were enrolled at 7 sites in the US. Under the original protocol patients received a bolus intravenous (IV) infusion of carfilzomib; patients enrolled under Amendments 2 to 4 received a 30-minute IV infusion.
| Milestone | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B LYM: CFZ 20/56 mg/m² | P1B LYM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 4 | 7 | 65 | 6 | 7 | 6 | 10 | 11 | 4 | 3 | 24 | 2 | 3 | 7 | 14 | 8 |
| Completed | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 |
| Not completed | 3 | 4 | 6 | 63 | 6 | 7 | 6 | 10 | 11 | 4 | 3 | 24 | 2 | 3 | 4 | 12 | 8 |
| Withdrew: Progressive disease | 1 | 3 | 5 | 42 | 4 | 4 | 3 | 8 | 6 | 3 | 3 | 14 | 2 | 1 | 2 | 11 | 5 |
| Withdrew: Adverse event | 0 | 1 | 1 | 7 | 0 | 2 | 3 | 2 | 3 | 0 | 0 | 5 | 0 | 1 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Other | 1 | 0 | 0 | 10 | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 |
Participants were evaluated for dose-limiting toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) version 3.0. A DLT was defined as treatment-related ≥ Grade 2 neuropathy with pain, ≥ Grade 3 non-hematologic toxicity, Grade 4 neutropenia or thrombocytopenia lasting 7 or more days, or thrombocytopenia with bleeding. The maximum tolerated dose (MTD) for each of the 3 populations (solid tumor, multiple myeloma, and lymphoma) was defined as the dose level at which \< 33% of participants experienced a dose-limiting toxicity during the first 28-day cycle.
| participants | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B LYM: CFZ 20/56 mg/m² | P1B LYM: CFZ 20/70 mg/m² |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT) | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 1 |
Overall response is defined as participants with a best overall response of complete response (CR), partial response (PR) or stable disease (SD) after 4 cycles, assessed by the Investigator using tumor measurement and according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target and non-target lesions and no new lesions; PR: Disappearance of all target lesions, persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits and no lesions, or, at least a 30% decrease in the size of target lesions and no progression of existing non-target lesions or any new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest size since the treatment started, and no progression of existing non-target lesions or any new lesions.
| percentage of participants | P2 ST: CFZ 20/36 mg/m² Bolus |
|---|---|
| Phase 2: Percentage of Participants With an Overall Response After 4 Treatment Cycles | 15.4 (7.6 to 26.5) |
Solid tumor participants were evaluated for disease response according to RECIST, Version 1.1. Multiple myeloma participants were evaluated using the International Myeloma Working Group (IMWG) Uniform Response Criteria with the addition of minimal response (MR) based on the European Group for Blood and Marrow Transplant Group (EBMT). Non-Hodgkin lymphoma (NHL) participants were evaluated using the International Workshop NHL criteria. Waldenström macroglobulinemia (WM) participants were evaluated using Criteria from the Sixth International Workshop for WM. Overall response is defined in Outcome Measure 2 for participants with solid tumors. For NHL, overall response is defined as a best overall response of CR or PR. For multiple myeloma and WM, overall response is defined as participants with a best overall response of stringent complete response (sCR), CR, very good partial response (VGPR) or PR.
| percentage of participants | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B NHL: CFZ 20/56 mg/m² | P1B NHL: CFZ 20/70 mg/m² | P1B WM: CFZ 20/56 mg/m² | P1B WM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With an Overall Response Throughout the Study | 100.0 (29.2 to 100.0) | 0.0 (0.0 to 60.2) | 42.9 (9.9 to 81.6) | 38.5 (26.7 to 51.4) | 33.3 (4.3 to 77.7) | 28.6 (3.7 to 71.0) | 50.0 (11.8 to 88.2) | 10.0 (0.3 to 44.5) | 36.4 (10.9 to 69.2) | 50.0 (6.8 to 93.2) | 33.3 (0.8 to 90.6) | 50.0 (29.1 to 70.9) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 100.0 (2.5 to 100.0) | 100.0 (39.8 to 100.0) | 64.3 (35.1 to 87.2) | 37.5 (8.5 to 75.5) |
Duration of response is defined as the time from first evidence of a partial response or better (the first observation of PR before confirmation) to disease progression, with deaths owing to causes other than progression censored.
| months | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B NHL: CFZ 20/56 mg/m² | P1B NHL: CFZ 20/70 mg/m² | P1B WM: CFZ 20/56 mg/m² | P1B WM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response | — | — | 6.2 (NA to NA) | — | — | — | — | — | — | 9.3 (3.9 to 14.7) | 5.5 (NA to NA) | 8.0 (4.1 to 32.5) | 14.8 (NA to NA) | — | — | NA (NA to NA) | NA (NA to NA) | 9.0 (1.9 to NA) | 22.6 (17.5 to 27.6) |
Progression-free survival (PFS) is the time from start of treatment to disease progression or death (due to any cause), whichever occurred first.
| months | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B NHL: CFZ 20/56 mg/m² | P1B NHL: CFZ 20/70 mg/m² | P1B WM: CFZ 20/56 mg/m² | P1B WM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progression-Free Survival | 5.1 (NA to NA) | 1.8 (1.6 to 1.9) | 1.8 (1.0 to NA) | 1.8 (1.7 to 2.1) | 1.7 (1.1 to NA) | 2.9 (0.9 to 15.4) | 1.4 (0.3 to 24.6) | 1.5 (0.3 to 2.0) | 1.6 (0.4 to 5.4) | 5.2 (4.4 to 15.1) | 4.6 (1.4 to 5.9) | 6.9 (1.2 to 8.4) | 9.4 (1.9 to 16.8) | NA (1.6 to NA) | 1.0 (0.6 to NA) | NA (NA to NA) | NA (NA to NA) | 4.6 (1.9 to 12.7) | 11.5 (1.8 to 28.0) |
Time to Progression (TTP) is defined as number of months between start of treatment and first evidence/documentation of disease progression.
| months | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B NHL: CFZ 20/56 mg/m² | P1B NHL: CFZ 20/70 mg/m² | P1B WM: CFZ 20/56 mg/m² | P1B WM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Progression | 5.1 (NA to NA) | 1.8 (1.6 to 1.9) | 1.8 (1.6 to NA) | 1.8 (1.7 to 2.1) | 1.7 (1.1 to NA) | 1.6 (0.9 to 4.1) | 1.6 (1.1 to NA) | 1.6 (0.5 to 2.0) | 1.6 (0.3 to 5.6) | 5.2 (4.4 to 15.1) | 4.6 (1.4 to 5.9) | 6.9 (1.2 to 8.4) | 9.4 (1.9 to 16.8) | NA (1.6 to NA) | 1.0 (0.6 to NA) | NA (NA to NA) | NA (NA to NA) | 4.6 (1.9 to 12.7) | 11.5 (1.8 to 28.0) |
Plasma concentrations of carfilzomib were determined by a validated liquid chromatography tandem mass spectrometry method. Concentration values that were below the lower limit of quantification of 0.1 ng/mL were set to zero. Treatment groups receiving the same dose (e.g. 20 mg/m²) were combined for Day 1 analyses.
| ng/mL | ST: CFZ 20 mg/m² Bolus | ST: CFZ 20 mg/m² | ST: CFZ 36 mg/m² | ST: CFZ 45 mg/m² | MM: CFZ 20 mg/m² |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration of Carfilzomib | 2390 ± 104 | 914 ± 58.2 | 1061 ± 50.7 | 1193 ± 197.3 | 722 ± 62.1 |
| hours | ST: CFZ 20 mg/m² Bolus | ST: CFZ 20 mg/m² | ST: CFZ 36 mg/m² | ST: CFZ 45 mg/m² | MM: CFZ 20 mg/m² |
|---|---|---|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Carfilzomib | 0.0500 (0 to 0.167) | 0.500 (0.0833 to 0.7500) | 0.258 (0.0833 to 0.500) | 0.275 (0.100 to 0.550) | 0.250 (0.0833 to 0.750) |
| h*ng/mL | ST: CFZ 20 mg/m² Bolus | ST: CFZ 20 mg/m² | ST: CFZ 36 mg/m² | ST: CFZ 45 mg/m² | MM: CFZ 20 mg/m² |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Last Concentration Measured (AUC0-last) for Carfilzomib | 251 ± 92.0 | 346 ± 57.4 | 426 ± 70.1 | 536 ± 150.4 | 269 ± 54.3 |
| h*ng/mL | ST: CFZ 20 mg/m² Bolus | ST: CFZ 20 mg/m² | ST: CFZ 36 mg/m² | ST: CFZ 45 mg/m² | MM: CFZ 20 mg/m² |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for Carfilzomib | 223 ± 104 | 324 ± 52.8 | 426 ± 70.1 | 538 ± 150.1 | 273 ± 55.3 |
| hours | ST: CFZ 20 mg/m² Bolus | ST: CFZ 20 mg/m² | ST: CFZ 36 mg/m² | ST: CFZ 45 mg/m² | MM: CFZ 20 mg/m² |
|---|---|---|---|---|---|
| Elimination Half-life (t½) of Carfilzomib | 0.444 (0.152 to 2.20) | 0.888 (0.368 to 2.33) | 0.917 (0.359 to 1.23) | 0.952 (0.810 to 2.11) | 0.888 (0.411 to 1.57) |
| liters/hour | ST: CFZ 20 mg/m² Bolus | ST: CFZ 20 mg/m² | ST: CFZ 36 mg/m² | ST: CFZ 45 mg/m² | MM: CFZ 20 mg/m² |
|---|---|---|---|---|---|
| Clearance (CL) of Carfilzomib | 263 ± 398 | 139 ± 70.1 | 182 ± 88.8 | 302 ± 438 | 164 ± 89.6 |
| liters | ST: CFZ 20 mg/m² Bolus | ST: CFZ 20 mg/m² | ST: CFZ 36 mg/m² | ST: CFZ 45 mg/m² | MM: CFZ 20 mg/m² |
|---|---|---|---|---|---|
| Volume of Distribution at Steady State (Vss) of Carfilzomib | 27.7 ± 48.6 | 31.0 ± 21.9 | 22.7 ± 24.2 | 113 ± 230 | 21.8 ± 24.6 |
| hours | ST: CFZ 20 mg/m² Bolus | ST: CFZ 20 mg/m² | ST: CFZ 36 mg/m² | ST: CFZ 45 mg/m² | MM: CFZ 20 mg/m² |
|---|---|---|---|---|---|
| Mean Residence Time (MRT) Extrapolated to Infinity for Carfilzomib | 0.0902 ± 0.0319 | 0.227 ± 0.150 | 0.116 ± 0.0828 | 0.205 ± 0.156 | 0.117 ± 0.0799 |
Collected over From the first administration of carfilzomib and within 30 days after the last dose of study treatment; maximum duration of treatment was 366 days for bolus administration and 1073 days for infusion. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| P1B ST: CFZ 20 mg/m² Bolus | — | 1/3 (33.3%) | 3/3 (100%) |
| P1B ST: CFZ 20/27 mg/m² Bolus | — | 1/4 (25%) | 4/4 (100%) |
| P1B ST: CFZ 20/36 mg/m² Bolus | — | 4/7 (57.1%) | 7/7 (100%) |
| P2 ST: CFZ 20/36 mg/m² Bolus | — | 27/65 (41.5%) | 65/65 (100%) |
| P1B ST: CFZ 36 mg/m² | — | 2/6 (33.3%) | 6/6 (100%) |
| P1B ST: CFZ 45 mg/m² | — | 4/7 (57.1%) | 7/7 (100%) |
| P1B ST: CFZ 20/45 mg/m² | — | 5/6 (83.3%) | 6/6 (100%) |
| P1B ST: CFZ 20/56 mg/m² | — | 5/10 (50%) | 10/10 (100%) |
| P1B ST: CFZ 20/70 mg/m² | — | 6/11 (54.5%) | 11/11 (100%) |
| P1B MM: CFZ 20/36 mg/m² | — | 2/4 (50%) | 4/4 (100%) |
| P1B MM: CFZ 20/45 mg/m² | — | 0/3 (0%) | 3/3 (100%) |
| P1B MM: CFZ 20/56 mg/m² | — | 11/24 (45.8%) | 24/24 (100%) |
| P1B MM: CFZ 20/70 mg/m² | — | 2/2 (100%) | 2/2 (100%) |
| P1B LYM: CFZ 20/56 mg/m² | — | 1/3 (33.3%) | 3/3 (100%) |
| P1B LYM: CFZ 20/70 mg/m² | — | 5/7 (71.4%) | 7/7 (100%) |
| P1B MM: CFZ 20/45 mg/m² + Dex | — | 5/14 (35.7%) | 14/14 (100%) |
| P1B MM: CFZ 20/56 mg/m² + Dex | — | 3/8 (37.5%) | 8/8 (100%) |
| Event | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1B MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B LYM: CFZ 20/56 mg/m² | P1B LYM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ProteinuriaRenal and urinary disorders | 0/3 | 0/4 | 0/7 | 0/65 | 0/6 | 0/7 | 0/6 | 0/10 | 0/11 | 0/4 | 0/3 | 0/24 | 1/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| Renal tubular necrosisRenal and urinary disorders | 0/3 | 0/4 | 0/7 | 0/65 | 0/6 | 0/7 | 0/6 | 0/10 | 0/11 | 0/4 | 0/3 | 0/24 | 1/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/3 | 0/4 | 0/7 | 0/65 | 0/6 | 0/7 | 0/6 | 0/10 | 0/11 | 0/4 | 0/3 | 0/24 | 1/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| Disease progressionGeneral disorders | 0/3 | 0/4 | 0/7 | 5/65 | 0/6 | 0/7 | 2/6 | 1/10 | 4/11 | 0/4 | 0/3 | 2/24 | 0/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| PainGeneral disorders | 1/3 | 0/4 | 0/7 | 2/65 | 0/6 | 0/7 | 0/6 | 0/10 | 1/11 | 0/4 | 0/3 | 0/24 | 0/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/4 | 0/7 | 1/65 | 0/6 | 1/7 | 1/6 | 0/10 | 0/11 | 0/4 | 0/3 | 0/24 | 0/2 | 1/3 | 2/7 | 0/14 | 0/8 |
| Coronary artery diseaseCardiac disorders | 0/3 | 0/4 | 0/7 | 0/65 | 0/6 | 0/7 | 0/6 | 0/10 | 0/11 | 1/4 | 0/3 | 0/24 | 0/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| PyrexiaGeneral disorders | 0/3 | 0/4 | 0/7 | 1/65 | 0/6 | 0/7 | 0/6 | 0/10 | 1/11 | 1/4 | 0/3 | 3/24 | 0/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 0/3 | 1/4 | 0/7 | 0/65 | 0/6 | 0/7 | 0/6 | 0/10 | 1/11 | 0/4 | 0/3 | 0/24 | 0/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 0/4 | 0/7 | 0/65 | 0/6 | 0/7 | 0/6 | 2/10 | 0/11 | 0/4 | 0/3 | 0/24 | 0/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| Event | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1B MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B LYM: CFZ 20/56 mg/m² | P1B LYM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/4 | 1/7 | 1/65 | 0/6 | 1/7 | 0/6 | 1/10 | 3/11 | 1/4 | 1/3 | 13/24 | 2/2 | 1/3 | 3/7 | 5/14 | 3/8 |
| FatigueGeneral disorders | 0/3 | 2/4 | 3/7 | 38/65 | 0/6 | 4/7 | 3/6 | 4/10 | 5/11 | 3/4 | 3/3 | 14/24 | 2/2 | 2/3 | 3/7 | 9/14 | 5/8 |
| PyrexiaGeneral disorders | 0/3 | 0/4 | 3/7 | 17/65 | 1/6 | 1/7 | 2/6 | 5/10 | 2/11 | 1/4 | 1/3 | 13/24 | 1/2 | 3/3 | 5/7 | 2/14 | 4/8 |
| NauseaGastrointestinal disorders | 0/3 | 0/4 | 4/7 | 28/65 | 2/6 | 4/7 | 2/6 | 4/10 | 6/11 | 3/4 | 2/3 | 13/24 | 1/2 | 1/3 | 1/7 | 4/14 | 3/8 |
| AstheniaGeneral disorders | 0/3 | 0/4 | 4/7 | 7/65 | 0/6 | 1/7 | 2/6 | 0/10 | 0/11 | 0/4 | 0/3 | 2/24 | 0/2 | 2/3 | 1/7 | 1/14 | 2/8 |
| ChillsGeneral disorders | 0/3 | 0/4 | 2/7 | 18/65 | 1/6 | 1/7 | 3/6 | 2/10 | 2/11 | 1/4 | 2/3 | 8/24 | 0/2 | 0/3 | 4/7 | 0/14 | 1/8 |
| Blood creatinine increasedInvestigations | 0/3 | 0/4 | 1/7 | 11/65 | 0/6 | 3/7 | 1/6 | 3/10 | 2/11 | 0/4 | 2/3 | 6/24 | 0/2 | 0/3 | 4/7 | 1/14 | 0/8 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 0/4 | 0/7 | 0/65 | 0/6 | 0/7 | 0/6 | 1/10 | 1/11 | 0/4 | 0/3 | 1/24 | 0/2 | 2/3 | 1/7 | 1/14 | 0/8 |
| HypomagnesaemiaMetabolism and nutrition disorders | 2/3 | 0/4 | 0/7 | 4/65 | 0/6 | 0/7 | 0/6 | 0/10 | 0/11 | 0/4 | 0/3 | 1/24 | 0/2 | 0/3 | 0/7 | 0/14 | 1/8 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/4 | 0/7 | 2/65 | 1/6 | 1/7 | 1/6 | 0/10 | 0/11 | 0/4 | 2/3 | 3/24 | 0/2 | 0/3 | 0/7 | 0/14 | 0/8 |
| Age, Continuous(years) | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B LYM: CFZ 20/56 mg/m² | P1B LYM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bolus Groups | 47.3 ± 14.74 | 60.8 ± 8.81 | 60.0 ± 11.72 | 62.0 ± 9.97 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 62.20 ± 10.43 |
| 30-minute Infusion Groups | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 60.0 ± 5.18 | 69.9 ± 11.10 | 61.2 ± 10.38 | 61.4 ± 7.40 | 61.6 ± 11.58 | 63.3 ± 3.77 | 72.0 ± 5.57 | 62.7 ± 9.88 | 69.5 ± 12.02 | 58.7 ± 10.69 | 65.4 ± 10.31 | 58.6 ± 9.54 | 58.3 ± 6.14 | 62.3 ± 9.47 |
| Sex: Female, Male(Participants) | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B LYM: CFZ 20/56 mg/m² | P1B LYM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 4 | 38 | 0 | 4 | 3 | 5 | 4 | 2 | 1 | 7 | 1 | 1 | 3 | 4 | 1 | 80 |
| Male | 2 | 3 | 3 | 27 | 6 | 3 | 3 | 5 | 7 | 2 | 2 | 17 | 1 | 2 | 4 | 10 | 7 | 104 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | P1B ST: CFZ 20 mg/m² Bolus | P1B ST: CFZ 20/27 mg/m² Bolus | P1B ST: CFZ 20/36 mg/m² Bolus | P2 ST: CFZ 20/36 mg/m² Bolus | P1B ST: CFZ 36 mg/m² | P1B ST: CFZ 45 mg/m² | P1B ST: CFZ 20/45 mg/m² | P1B ST: CFZ 20/56 mg/m² | P1B ST: CFZ 20/70 mg/m² | P1B MM: CFZ 20/36 mg/m² | P1B MM: CFZ 20/45 mg/m² | P1b MM: CFZ 20/56 mg/m² | P1B MM: CFZ 20/70 mg/m² | P1B LYM: CFZ 20/56 mg/m² | P1B LYM: CFZ 20/70 mg/m² | P1B MM: CFZ 20/45 mg/m² + Dex | P1B MM: CFZ 20/56 mg/m² + Dex | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 3 | 4 | 27 | 2 | 1 | 0 | 2 | 4 | 4 | 0 | 8 | 0 | 2 | 3 | 7 | 5 | 73 |
| 1 | 2 | 1 | 3 | 35 | 4 | 4 | 6 | 7 | 7 | 0 | 2 | 15 | 1 | 0 | 3 | 6 | 3 | 99 |
| 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 9 |
| Missing | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
The record gives a start of Sep 2007, a primary completion of Oct 2014 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib